Trials / Completed
CompletedNCT01419041
A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function
A Phase I, Single Dose, Parallel-Group Study To Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The present study is being conducted to evaluate whether or not severe renal impairment has an effect on crizotinib Pharmacokinetics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | crizotinib | Single-dose oral 250 mg crizotinib in subjects with normal renal function (CLcr =\>90 mL/min) |
| DRUG | crizotinib | Single-dose oral 250 mg crizotinib in subjects with severe renal impairment (CLcr \<30 mL/min) |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2011-08-17
- Last updated
- 2012-10-01
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01419041. Inclusion in this directory is not an endorsement.